New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has accepted Alnylam’s enzymatic ligation ...
FDA has accepted Alnylam’s enzymatic ligation manufacturing platform into its Emerging Technology Program, fast-tracking global regulatory engagement CAMBRIDGE, Mass., December 17, 2025--(BUSINESS ...
Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet global RNAi therapeutics demand. The expansion supports Alnylam's pipeline ...
The U.S. Food and Drug Administration has accepted Alnylam’s enzymatic ligation manufacturing platform, called siRELIS, into its Emerging Technology Program, which will accelerate regulatory dialogue ...
Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback